USD 2.5 billion
Report ID:
SQMIG35I2243 |
Region:
Global |
Published Date: May, 2025
Pages:
157
|Tables:
35
|Figures:
74
Global Cannabis Pharmaceuticals Market size was valued at USD 2.5 billion in 2023 and is poised to grow from USD 3.93 billion in 2024 to USD 145.72 billion by 2032, growing at a CAGR of 57.1% during the forecast period (2025-2032).
The widespread utilization of cannabis across various medical applications is a significant catalyst for market growth. Cannabis products can be applied to manage a number of illnesses. Some chronic conditions that cannabis can be applied in are arthritis and cancer, along with Parkinson’s and Alzheimer’s disease. Cannabis can also be used to manage neurological disorders such as depression, epilepsy, and anxiety.
These ingredients help reduce patient pain. The continued intake of these products has grown due to its requirement in easing chronic pain and its importance in pain management medications. These factors have boosted the growth of the market in recent years.
Several countries all around the world have decriminalized cannabis, making its usage legal in therapy products. These nations include Cyprus, Finland, Chile, Canada, Croatia, Colombia, the US and UK, Denmark, Poland, Czech Republic, and Portugal, among others. The trend of opening up the legality of cannabis products due to its therapeutic properties has helped market growth immensely.
This trend can be shown in one perfect example. In May 2021, the MORE (Marijuana Opportunity, Reinvestment, and Expungement) Act was reinstated in the U.S. House of Representatives. This highlights the region’s support for legalization of cannabis in therapy. This spark will light the fire in other regions as well, offering a growth opportunity for the global market.
Governments and consumers around the world are starting to accept cannabis. This global acceptance has also resulted in health professionals prescribing therapies that include these products. This in turn opens up the market for a potentially extended period of expansion. This trend is gaining popularity and will help the market maintain its steady growth.
Market snapshot - 2025-2032
Global Market Size
USD 2.5 billion
Largest Segment
epidiolex
Fastest Growth
sativex
Growth Rate
57.1% CAGR
To get more reports on the above market click here to Buy The Report
Global Cannabis Pharmaceuticals Market is segmented by Distribution Channel, Product and region. Based on Product, the market is segmented into Sativex, Cesamet, Marinol and Epidiolex. Based on Distribution Channel, the market is segmented into Online Pharmacies, Hospitals and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
In terms of brand classification, the segment that comes out on top as the leading revenue generator is Epidiolex, which holds a substantial share of 97.5% as of 2022. The sales of this market segment have boomed exponentially in recent years thus crediting its current position in the market. Furthermore, significant support for the expansion of this market segment has been generated due to the approval of pricing and reimbursement in countries like Israel, Finland, and Germany. he increasing number of approvals for its use as a vital medication in the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, have continued to propel the expansion of this segment.
On the other hand, the “other” brands segment is predicted to develop into the most lucrative market, displaying rapid growth throughout the forecast period at a noteworthy rate of 76.1%. The dynamics of the market will be greatly transformed due to these forthcoming product launch. For example, SciSparc announced the beginning of their recruitment drive, in January 2022, for the first patient in a Phase-IIa clinical trial that targets the medicinal purposes of the cannabis-related compound SCI-110. Usually, Phase-II studies utilize an average of 2 to 5 years for completion before the product can be launched into the market. As a result of these developments, these impending product launches are ready to contribute heavily to market expansion.
To get detailed analysis on other segments, Request For Free Sample Report
North America, led by countries like the United States and Canada, has been one of the most prominent regions in the global cannabis pharmaceutical market. In recent years, North America has seen a boom in both medical and recreational cannabis legalization, further stimulating market growth. Driven by the increasing acceptance of cannabis as a treatment option and the availability of multiple cannabis-derived pharmaceuticals, the United States, in particular, has seen a tremendous development in the use of cannabis for medicinal purposes. Moreover, North America's rich ecosystem of research and development and the presence of major cannabis pharmaceutical companies greatly contribute to retaining its position in the market.
On the other hand, the Asia-Pacific region has presented the cannabis pharmaceutical market with opportunities and challenges alike. Though there is a growing awareness of the potential medical benefits of cannabis products, several countries in the region have continued to maintain strict regulations against these products. Nevertheless, an increasing acceptance of alternative medicine and the changing perception of cannabis globally, is gradually influencing the market in this region. Additionally, some Asian countries, such as Israel and Australia, have come a long way in cannabis research and have legalized medical cannabis use, which seems to be a good sign for regional market growth. In the long term, the expanding healthcare infrastructure and large population of the Apac region holds a promising ideal for the development of the cannabis pharmaceutical market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Legalization and Regulatory Changes
Growing Acceptance of Medical Cannabis
Rising Chronic Diseases
Regulatory Challenges
Lack of Clinical Evidence
Stigma and Misconceptions
Request Free Customization of this report to help us to meet your business objectives.
Several companies in the market are captured in fierce competition as they strive to expand the range of medical conditions that can be treated with cannabis-derived compounds by putting in significant investments in research and development to discover new cannabinoid-based pharmaceuticals. These efforts include the conduction of clinical trials to research and establish the safety and efficacy of cannabis products. In order to speed up market penetration and product development, these companies are employing strategic collaborations. Companies were bringing in a diverse range of offerings to their existing product portfolios by developing various forms of cannabis-based medicines, including transdermal patches, inhalers, oral medications, and more, thus allowing them to cater to a wider range of patient needs and preferences.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Product types team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global Pretreatment Coatings Market analysis, the global cannabis pharmaceuticals market has experienced remarkable growth and transformation over the past few years. The increasing acceptance of medical cannabis as a legitimate treatment option for various medical conditions, coupled with evolving regulatory frameworks in numerous countries, has propelled the market forward. Key players like GW Pharmaceuticals and Tilray have played pivotal roles in advancing research and development efforts, resulting in the approval of groundbreaking cannabis-based medications.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 2.5 billion |
Market size value in 2032 | USD 145.72 billion |
Growth Rate | 57.1% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Cannabis Pharmaceuticals Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cannabis Pharmaceuticals Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cannabis Pharmaceuticals Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cannabis Pharmaceuticals Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
Global Cannabis Pharmaceuticals Market size was valued at USD 2.5 billion in 2023 and is poised to grow from USD 3.93 billion in 2024 to USD 145.72 billion by 2032, growing at a CAGR of 57.1% during the forecast period (2025-2032).
Several companies in the market are captured in fierce competition as they strive to expand the range of medical conditions that can be treated with cannabis-derived compounds by putting in significant investments in research and development to discover new cannabinoid-based pharmaceuticals. These efforts include the conduction of clinical trials to research and establish the safety and efficacy of cannabis products. In order to speed up market penetration and product development, these companies are employing strategic collaborations. Companies were bringing in a diverse range of offerings to their existing product portfolios by developing various forms of cannabis-based medicines, including transdermal patches, inhalers, oral medications, and more, thus allowing them to cater to a wider range of patient needs and preferences. 'Jazz Pharmaceuticals plc (Ireland) ', 'Insys Therapeutics, Inc. (USA) ', 'Corbus Pharmaceuticals Holdings, Inc. (USA) ', 'Botanix Pharmaceuticals Ltd (Australia) ', 'GW Pharmaceuticals (UK) ', 'Canopy Growth Corporation (Canada) ', 'Tilray Brands, Inc. (USA) ', 'Aurora Cannabis Inc. (Canada) ', 'Almac Group (UK) ', 'Catalent, Inc. (USA) ', 'Cara Therapeutics, Inc. (USA) ', 'Axim Biotechnologies, Inc. (USA) ', 'Emerald Health Therapeutics, Inc. (Canada) ', 'MediPharm Labs Corp. (Canada) ', 'Creso Pharma Limited (Australia) ', 'ECS Botanics (Australia) ', 'Neurotech International (Australia) ', 'Emyria Limited (Australia)'
A prominent driver in the cannabis pharmaceutical market is the growing rate of legalization of medical cannabis in various countries and states. As more areas accept and permit the use of cannabis for medicinal purposes, it strengthens the market's potential.
Diverse Product Formats: Consumer choice and accessibility of cannabis products is increasing with the introduction of an expanding range of product formats, including edibles, oils, and capsules.
North America, led by countries like the United States and Canada, has been one of the most prominent regions in the global cannabis pharmaceutical market. In recent years, North America has seen a boom in both medical and recreational cannabis legalization, further stimulating market growth. Driven by the increasing acceptance of cannabis as a treatment option and the availability of multiple cannabis-derived pharmaceuticals, the United States, in particular, has seen a tremendous development in the use of cannabis for medicinal purposes. Moreover, North America's rich ecosystem of research and development and the presence of major cannabis pharmaceutical companies greatly contribute to retaining its position in the market.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35I2243
[email protected]
USA +1 351-333-4748